文献速递角膜与眼表疾病

特应性皮炎患者中度普利尤单抗诱导的眼表疾病(DIOSD):临床表现、发病危险因素及他克莫司软膏治疗结局

Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment.
PubMed 文献 · Br J Ophthalmol · 2019-09-25

在以色列Rabin医学中心开展回顾性机构队列研究,纳入2018年3月至2019年6月接受度普利尤单抗治疗的37例成人特应性皮炎患者。16例(43%)在首次治疗后2周起出现新发或加重的眼表疾病症状,严重特应性皮炎是最强预测因素,既往特应性角结膜炎为危险因素,特应性家族史为保护因素;4例睑结膜炎患者使用0.03%-0.1%他克莫司软膏后症状和体征均在数日内消退。

要点

  • 37例成人特应性皮炎患者中16例(43%)出现度普利尤单抗诱导的眼表疾病,多从首次治疗后2周开始。
  • 严重特应性皮炎是最强预测因素,中度特应性皮炎患者无一例发生度普利尤单抗诱导的眼表疾病。
  • 既往特应性角结膜炎为危险因素(OR=23.28,p=0.005),特应性家族史为保护因素(OR=0.13,p=0.05)。

核心结论

  • 度普利尤单抗诱导的眼表疾病在接收度普利尤单抗治疗的特应性皮炎患者中常见,多数病例较轻,部分患者可发生睑结膜炎且对他克莫司软膏反应良好。
  • 特应性皮炎严重程度和既往特应性角结膜炎是度普利尤单抗诱导的眼表疾病的危险因素。

研究设计与样本

  • 在以色列Petach Tikva的Rabin医学中心开展的回顾性机构队列研究。
  • 纳入2018年3月至2019年6月接受度普利尤单抗治疗的成人特应性皮炎患者37例。
  • 记录人口学资料、特应性皮炎严重程度评分、血IgE水平、既往特应性角结膜炎、对度普利尤单抗的皮肤病学反应、眼科评估和治疗。
  • 采用单因素和多因素分析识别度普利尤单抗诱导的眼表疾病的危险因素。

主要发现

  • 37例患者中16例(43%)在首次治疗后2周起出现新发或加重的眼表疾病症状。
  • 3例报告持续2周的暂时性眼干涩感,9例报告慢性眼干涩感,4例(25%)出现明显的睑结膜炎。
  • 严重特应性皮炎是度普利尤单抗诱导的眼表疾病的最强预测因素,中度特应性皮炎患者无一例发生。
  • 多因素分析中,既往特应性角结膜炎是度普利尤单抗诱导的眼表疾病的危险因素(R2=15.78,OR=23.28,p=0.005)。
  • 多因素分析中,特应性家族史对度普利尤单抗诱导的眼表疾病具有保护作用(R2=6.22,OR=0.13,p=0.05)。

关键数值与推荐

  • 既往特应性角结膜炎:OR=23.28(p=0.005),为度普利尤单抗诱导的眼表疾病的危险因素。
  • 特应性家族史:OR=0.13(p=0.05),对度普利尤单抗诱导的眼表疾病具有保护作用。
  • 4例睑结膜炎患者使用眼部周围0.03%-0.1%他克莫司软膏后体征和症状均在数日内消退。

临床怎么用

  • 作者报告4例睑结膜炎患者经眼部周围0.03%-0.1%他克莫司软膏治疗后体征和症状均在数日内消退。
  • 作者认为特应性皮炎严重程度和既往特应性角结膜炎是度普利尤单抗诱导的眼表疾病的危险因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To identify risk factors for the development of dupilumab-induced ocular surface disease (DIOSD) in adult patients with atopic dermatitis (AD) and describe outcomes of treatment. METHODS: A retrospective institutional cohort study performed at the Rabin Medical Center, Petach Tikva, Israel. Adult patients with AD who received dupilumab from March 2018 to June 2019 were included. Demographics, AD severity scores, blood IgE levels, previous atopic keratoconjunctivitis (AKC), dermatological response to dupilumab, ophthalmological evaluation and treatment were noted. Univariate and multivariate analyses were used to identify risk factors for DIOSD. RESULTS: Sixteen of 37 patients who were included in the study (43%) had new or exacerbated symptoms of ocular surface disease starting at 2 weeks following the first treatment. Three patients reported transient dry eye sensation which lasted 2 weeks; nine patients reported chronic dry eye sensation, and four patients (25%) had marked blepharoconjunctivitis. The presence of severe AD was the strongest predictor of DIOSD. Not a single patient with moderate AD had DIOSD. In multivariate analysis, prior AKC was a risk factor for DIOSD (R2=15.78, OR=23.28, p=0.005) while a family history of atopy was protective of DIOSD (R2=6.22, OR=0.13, p=0.05). All four patients with blepharoconjunctivitis had resolution of signs, and symptoms within days of starting periocular 0.03%-0.1% tacrolimus ointment. CONCLUSIONS: DIOSD is common in patients with AD receiving dupilumab. While most cases are mild, some patients can develop blepharoconjunctivitis which responds well to tacrolimus ointment. AD severity, and previous AKC are risk factors for DIOSD.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Nahum Y, Mimouni M, Livny E, et al. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol. 2019. PMID: 31554632. doi:10.1136/bjophthalmol-2019-315010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。